Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naive Schizophrenia Patients
Open Access
- 20 May 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14, 484
- https://doi.org/10.3389/fnins.2020.00484
Abstract
Patients with chronic schizophrenia often display enlarged striatal volumes, and antipsychotic drugs may contribute via the dopamine D-2/3 receptor (D2/3R) blockade. Separating the effects of disease from medication is challenging due to the lack of a proper placebo-group. To address this, we conducted a longitudinal study of antipsychotic-naive, first-episode schizophrenia patients to test the hypothesis that selective blockade of D2/3R would induce a dose-dependent striatal volume increase. Twenty-one patients underwent structural magnetic resonance imaging (sMRI), single-photon emission computed tomography (SPECT), and symptom severity ratings before and after six weeks of amisulpride treatment. Twenty-three matched healthy controls underwent sMRI and baseline SPECT. Data were analyzed using repeated measures and multiple regression analyses. Correlations between symptom severity decrease, volume changes, dose and receptor occupancy were explored. Striatal volumes did not differ between patients and controls at baseline or follow-up, but a significant group-by-time interaction was found (p = 0.01). This interaction was explained by a significant striatal volume increase of 2.1% in patients (Cohens d = 0.45). Striatal increase was predicted by amisulpride dose, but not by either D2/3R occupancy or baseline symptom severity. A significant reduction in symptom severity was observed at a mean dose of 233.3 (SD = 109.9) mg, corresponding to D2/3R occupancy of 44.65%. Reduction in positive symptoms correlated significantly with striatal volume increase, driven by reductions in hallucinations. Our data demonstrate a clear link between antipsychotic treatment and striatal volume increase in antipsychotic-naive schizophrenia patients. Moreover, the treatment-induced striatal volume increase appears clinically relevant by correlating to reductions in core symptoms of schizophrenia.Funding Information
- Lundbeckfonden
This publication has 56 references indexed in Scilit:
- Estimated Dopamine D2 Receptor Occupancy and Remission in SchizophreniaJournal of Clinical Psychopharmacology, 2013
- Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 SubjectsSchizophrenia Bulletin, 2012
- Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem ConfirmationBiological Psychiatry, 2012
- Dopamine D2 Receptor Occupancy and Clinical EffectsJournal of Clinical Psychopharmacology, 2011
- A Bayesian model of shape and appearance for subcortical brain segmentationNeuroImage, 2011
- Brain Volume Changes After Withdrawal of Atypical Antipsychotics in Patients With First-Episode SchizophreniaJournal of Clinical Psychopharmacology, 2011
- Lifetime cigarette smoking is associated with striatal volume measuresAddiction Biology, 2011
- Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoringActa Psychiatrica Scandinavica, 2009
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Strukturelles Neuroimaging der Basalganglien bei Schizophrenie: ein ReviewWiener Medizinische Wochenschrift, 2008